DIGESTION SUPPLEMENTED WITH COMMERCIAL GLUTENASES: EVALUATION OF THE FATE OF GLUTEN IN PIZZA BY PROTEOMICS AND IMMUNOCHEMISTRY

UEG Presentation

EFFICACY AND SAFETY OF THE GLUTENASE TAK-062 IN PATIENTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Log in to access this content.

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Introduction

Currently, the only management option for patients with celiac disease (CeD) is lifelong adherence to a gluten-free diet (GFD). Here, we report the results of a phase 2 study of the computationally designed glutenase TAK-062 (zamaglutenase) for the treatment of CeD in patients on a GFD (NCT05353985).

Aims & Methods

Eligible patients were aged >18 years with ongoing CeD-related gastrointestinal (GI) symptoms and villous height to crypt depth ratio (Vh:Cd) <2.5, despite maintenance of a GFD for ≥1 year. Study phases were: (1) a 4-week screening period to confirm symptoms and perform endoscopy; (2) a 4-week single-blind placebo run-in, including 2 weeks receiving placebo simulated inadvertent gluten exposure (SIGE) bars (Weeks −4 to −2) and 2 weeks receiving SIGE bars containing approximately 500 mg of gluten 3× per week (TIW; Week −2 to Day 1); and (3) a 24-week treatment period with patients randomized to receive TAK-062 600 mg or placebo with meals 3× per day (TID), plus gluten-containing SIGE TIW, followed by an endoscopy. Symptoms were assessed daily using the 5-item Celiac Disease Symptom Diary v2.1 (CDSD), that evaluates the severity of CeD symptoms on a 5-point Likert scale.

The primary endpoint was change from baseline to Week 12 in mean weekly CDSD GI symptom severity scores, and the secondary endpoint was change from baseline to Week 24 in Vh:Cd. Safety was assessed throughout the study. Differences between groups were assessed using a mixed model for repeated measures (primary endpoint) and ANCOVA (secondary endpoint) at a 2-sided significance level of 0.05.

Results

A total of 153 patients were randomized (placebo: n = 76; TAK-062: n = 77); one patient in the TAK-062 arm did not receive treatment. Mean age was 46.0 years, 75.2% of patients were female, mean time since diagnosis was 8.7 years, and 24.2% were seropositive. Mean baseline Vh:Cd was 1.78 and mean baseline weekly CDSD GI symptom severity score was 0.93. There were no appreciable differences between groups in baseline characteristics.

There was no significant improvement in weekly CDSD GI symptom severity score from baseline to Week 12 in either arm, and no significant difference between groups; non-significant improvements of approximately 0.1 were observed in both arms (Table). Vh:Cd remained stable to Week 24 in the placebo arm, but significantly decreased by 0.34 (95% confidence interval: −0.53, −0.14) in the TAK-062 arm, with a significant difference between groups (Table). Similar results were observed in all subgroups assessed.

TAK-062 was clinically well tolerated despite the significant decrease in Vh:Cd, with comparable proportions of patients in both arms experiencing an adverse event (AE) (placebo: 64.5%; TAK-062: 73.7%) or serious AE (placebo: 5.3%; TAK-062: 1.3%). The most frequent AEs were GI-related and occurred at a similar frequency in both arms, with the exception of diarrhea (placebo: 2.6%; TAK-062: 17.1%).

Table. Change from baseline in weekly CDSD GI symptom severity score to Week 12 and Vh:Cd to Week 24, among patients receiving TAK-062 and placebo
Results in bold are statistically significant. Discrepancies in change from baseline values are due to rounding. Δ, change from baseline; CDSD, Celiac Disease Symptom Diary; CI, confidence interval; GI, gastrointestinal; LS, least-squares; SE, standard error; SIGE, simulated inadvertent gluten exposure; Vh:Cd, villous height to crypt depth ratio.
		Placebo + SIGE n = 76	TAK-062 + SIGE n = 77	TAK-062 vs. placebo
Δ CDSD GI symptom severity score to Week 12	LS mean (SE) 95% CI (p value)	–0.128 (0.083) –0.292, 0.035 (0.124)	–0.111 (0.082) –0.272, 0.050 (0.176)	0.017 –0.162, 0.197 (0.847)
Δ Vh:Cd to Week 24	LS mean (SE) 95% CI (p value)	–0.006 (0.100) –0.201, 0.189 (0.951)	–0.338 (0.099) −0.531, −0.144 (< 0.001)	–0.331 –0.481, –0,181 (< 0.001)

Conclusion

TAK-062 did not demonstrate efficacy for improving symptoms or histology in patients with ongoing active CeD on a GFD. Vh:Cd significantly worsened in the TAK-062 arm, with a significant difference between groups; possible reasons for this are under investigation. Stable Vh:Cd in the placebo arm indicates that SIGE successfully mitigates trial-related disease improvements previously observed in similar cohorts.

Disclosure

LE has nothing to disclose. ML reports receiving consulting fees from Anokion, EllaOla, and Takeda, and research funding from Moderna (institution) and Takeda (institution). PR has nothing to disclose. CC has nothing to disclose. JS reports receiving consulting fees from Chugai, GIG, and Takeda, and research funding from Takeda. JAM reports grants from ImmusanT, National Institutes of Health, Department of Defense, Immunogenix, Takeda Pharmaceuticals, Allakos, Provention Bio, Oberkotter Foundation, and 9 Meters Biopharma; a contract (to institution) from Kanyos Bio (a wholly owned subsidiary of Anokion); consultancy fees from Johnson and Johnson, Bristol Myers Squibb, Intrexon Corporation, Dren Bio, Neoleukin Therapeutics, Reistone Biopharma, Immunic Therapeutics, Senda Biosciences, Brightseed Bio, Chugai Pharma, Alimentiv, Equillium, Interlude Biopharma, Ukko Inc., argenx; has received royalties from Torax Medical and Evelo Biosciences; and holds shares in Entero Healthcare and Minnesota Medical Technologies. DSS reports receiving honoraria and research funding from Takeda. HL, JRM, MZ, SG, and DAL are employees and shareholders of Takeda.

EFFICACY AND SAFETY OF THE GLUTENASE TAK-062 IN PATIENTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Luca Elli 1, Maureen M. Leonard 2, Piotr Rozpondek 3, Carolina Ciacci 4, Jocelyn Silvester 5, Joseph Murray 6, David Surendran Sanders 7, Hong Li 8, Joseph R. Maxwell 9, Mahsa Zarei 8, Sonal Ghura 8, Daniel A. Leffler 8

1 Granda Ospedale Maggiore Policlinico, Milano, Italy

2 MassGeneral Hospital for Children, Boston, United States

3 FutureMeds, Krakow, Poland

4 University of Salerno, Salerno, Italy

5 Boston Children’s Hospital, Boston, United States

6 Mayo Clinic, Rochester, United States

7 University of Sheffield, Sheffield, United Kingdom

8 Takeda Development Center Americas, Inc., Cambridge, United States

9 Takeda, Cambridge, United States

Event

UEG Week Berlin 2025

Topics

Mechanisms & Personalised Medicine Small Intestine & Nutrition

Submission format

Abstract

Session

Coeliac disease: From screening to new drugs

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

	Non-responsive Celiac disease	Responsive Celiac disease	Seronegative controls
Age[mean +/- SD]	50.5 ± 15.5	40.9 ± 16.6	45.4 ± 15.7
Gender (female) [percent of total]	86%	73%	71%
Duration of gluten-free diet, years [mean +/- se]	5.5 ± 6.3	6.1 ± 7.2	N/A
IL-15 levels in serum samples (pg/mL)[median (interquantile range)]	7.4 (6.3-8.9)	6.9 (5.7-7.9)	6.7 (5.5-8.0)
IL-15 levels in duodenal biopsy tissue samples (pg/mg)[median (interquantile range)]	0.71 (0.58-0.96)	0.60 (0.48-0.86)	0.77 (0.60-0.9)

UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Most popular content

Rate for better recommendations!